The PRAISE study: A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of iloprost in the early postoperative period after liver transplantation (ISRCTN12622749)

BMC Surgery

Utz Settmacher⁴  Karin Jandt³  Maria Breternitz¹  Heike Hoyer²  Falk Rauchfuß⁴  Erik Bärthel⁴ 

[1] Center for Clinical Studies, Jena, Germany;Institute of Medical Statistics, Information Sciences and Documentation, Jena, Germany;Department of General, Visceral and Vascular Surgery, Jena University Hospital, Erlanger Allee 101, D-07740, Jena, Germany;Center for Sepsis Control and Care, Jena University Hospital, Friedrich Schiller University, Jena, Germany

关键词: Prostaglandins;    Ischemia-reperfusion injury;    Initial non-function;    Primary graft dysfunction;    Liver transplantation;   

Others  :  1123347
DOI  :  10.1186/1471-2482-13-1

 received in 2012-11-23, accepted in 2013-01-23,  发布年份 2013

【 摘 要 】

Background

Liver graft dysfunction can deteriorate to complete organ failure and increases perioperative morbidity and mortality after liver transplantation. Therapeutic strategies reducing the rate of graft dysfunction are of current clinical relevance. One approach is the systemic application of prostaglandins, which were demonstrated to be beneficial in reducing ischemia-reperfusion injury. Preliminary data indicate a positive effect of prostacyclin analogue iloprost on allograft viability after liver transplantation. The objective of the study is to evaluate the impact of iloprost in a multi-center trial.

Methods/Design

A prospective, double-blinded, randomized, placebo-controlled multicenter study in a total of 365 liver transplant recipients was designed to assess the effect of intravenous iloprost after liver transplantation. Primary endpoint will be the primary graft dysfunction characterized as presentation of one or more of the following criteria: ALAT or ASAT level > 2000 IU/ml within the first 7 postoperative days, bilirubine ≥ 10 mg/dl on postoperative day 7; INR ≥ 1.6 on postoperative day 7 or initial non-function. Secondary endpoints are parameters of post-transplant morbidity, like rates of infections, biliary complications, need of clotting factors or renal replacement therapy and the graft and patient survival.

Discussion

A well-established treatment concept to avoid graft dysfunction after liver transplantation does not exist at the moment. If the data of this research project confirm prior findings, iloprost would improve the general outcome after liver transplantation.

Trial Registration

German Clinical Trials Register: DRKS00003514. Current Controlled Trials Register: ISRCTN12622749.

【 授权许可】

   
2013 Bärthel et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Schemmer P, et al.: Extended donor criteria have no negative impact on early outcome after liver transplantation: a single-center multivariate analysis. Transplant Proc 2007, 39(2):529-534.
• [2]Pokorny H, et al.: Organ survival after primary dysfunction of liver grafts in clinical orthotopic liver transplantation. Transpl Int 2000, 13(Suppl 1):S154-S157.
• [3]Ploeg RJ, et al.: Risk factors for primary dysfunction after liver transplantation–a multivariate analysis. Transplantation 1993, 55(4):807-813.
• [4]Deschenes M, et al.: Early allograft dysfunction after liver transplantation: a definition and predictors of outcome. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transplantation 1998, 66(3):302-310.
• [5]Chen H, et al.: Multi-factor analysis of initial poor graft function after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 2007, 6(2):141-146.
• [6]Johnson SR, et al.: Primary nonfunction (PNF) in the MELD Era: an SRTR database analysis. Am J Transplant 2007, 7(4):1003-1009.
• [7]Nanashima A, et al.: Analysis of initial poor graft function after orthotopic liver transplantation: experience of an australian single liver transplantation center. Transplant Proc 2002, 34(4):1231-1235.
• [8]Fondevila C, Busuttil RW, Kupiec-Weglinski JW: Hepatic ischemia/reperfusion injury–a fresh look. Exp Mol Pathol 2003, 74(2):86-93.
• [9]Tauber S, Menger MD, Lehr H-A: Microvascular in vivo assessment of reperfusion injury: significance of prostaglandin E1 and I2 in postischemic "no-reflow" and "reflow-paradox". J Surg Res 2004, 120(1):1-11.
• [10]Pokorny H, et al.: Influence of cumulative number of marginal donor criteria on primary organ dysfunction in liver recipients. Clin Transplant 2005, 19(4):532-536.
• [11]Lee SH, Rubin LJ: Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005, 258(3):199-215.
• [12]Beirne C, Hynes N, Sultan S: Six years' experience with prostaglandin I2 infusion in elective open repair of abdominal aortic aneurysm: a parallel group observational study in a tertiary referral vascular center. Ann Vasc Surg 2008, 22(6):750-755.
• [13]de Donato G, et al.: The ILAILL study: iloprost as adjuvant to surgery for acute ischemia of lower limbs: a randomized, placebo-controlled, double-blind study by the italian society for vascular and endovascular surgery. Ann Surg 2006, 244(2):185-193.
• [14]Barthel E, et al.: Impact of stable PGI(2) analog iloprost on early graft viability after liver transplantation: a pilot study. Clin Transplant 2012, 26(1):E38-E47.
• [15]Haller GW, et al.: Factors relevant to the development of primary dysfunction in liver allografts. Transplant Proc 1995, 27(1):1192.
• [16]Heise M, et al.: A survival-based scoring-system for initial graft function following orthotopic liver transplantation. Transpl Int 2003, 16(11):794-800.
• [17]Briceno J, et al.: Influence of marginal donors on liver preservation injury. Transplantation 2002, 74(4):522-526.
• [18]Riediger C, et al.: T-Tube or no T-tube in the reconstruction of the biliary tract during orthotopic liver transplantation: systematic review and meta-analysis. Liver Transpl 2010, 16(6):705-717.
• [19]Olthoff KM, et al.: Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl 2010, 16(8):943-949.
• [20]Cavalcanti AB, et al.: Prostaglandins for adult liver transplanted patients. Cochrane Database Syst Rev 2011, 11:CD006006.
• [21]Rubin RH: The direct and indirect effects of infection in liver transplantation: pathogenesis, impact, and clinical management. Curr Clin Top Infect Dis 2002, 22:125-154.
• [22]Paugam-Burtz C, et al.: Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors. Liver Transpl 2009, 15(5):522-529.
• [23]Honkonen EL, et al.: Dopexamine unloads the impaired right ventricle better than iloprost, a prostacyclin analog, after coronary artery surgery. J Cardiothorac Vasc Anesth 1998, 12(6):647-653.
• [24]Biggins SW, et al.: Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002, 8(4):313-322.
• [25]Kurokawa T, et al.: Effects of prostaglandin E1 on the recovery of ischemia-induced liver mitochondrial dysfunction in rats with cirrhosis. Scand J Gastroenterol 1991, 26(3):269-274.
• [26]Klein M, et al.: Preconditioning of donor livers with prostaglandin I2 before retrieval decreases hepatocellular ischemia-reperfusion injury. Transplantation 1999, 67(8):1128-1132.
• [27]Natori S, et al.: Prostaglandin E1 protects against ischemia-reperfusion injury of the liver by inhibition of neutrophil adherence to endothelial cells. Transplantation 1997, 64(11):1514-1520.
• [28]Totsuka E, et al.: Attenuation of ischemic liver injury by prostaglandin E1 analogue, misoprostol, and prostaglandin I2 analogue, OP-41483. J Am Coll Surg 1998, 187(3):276-286.
• [29]Neumann UP, et al.: Reduction of reperfusion injury with prostacyclin I2 after liver transplantation. Transplant Proc 1999, 31(1–2):1029-1030.
• [30]Kornberg A, et al.: Impact of selective prostaglandin E1 treatment on graft perfusion and function after liver transplantation. Hepatogastroenterology 2004, 51(56):526-531.
• [31]Giostra E, et al.: Prophylactic administration of prostaglandin E1 in liver transplantation: results of a pilot trial. Transplant Proc 1997, 29(5):2381-2384.
• [32]Henley KS, et al.: A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology 1995, 21(2):366-372.
• [33]Klein AS, et al.: Prostaglandin E1 administration following orthotopic liver transplantation: a randomized prospective multicenter trial. Gastroenterology 1996, 111(3):710-715.